Emalex is focused on developing ecopipam, a first-in-class drug being evaluated for the treatment of Tourette’s Syndrome and Childhood-Onset Fluency Disorder (stuttering) in adults
Emalex is focused on developing ecopipam, a first-in-class drug being evaluated for the treatment of Tourette’s Syndrome and Childhood-Onset Fluency Disorder (stuttering) in adults.